Business
NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions - Adds New U.S. Patent to Portfolio
Company receives notice of the issuance of a U.S. patent covering the lead formulation, NRX-101, a glycine site NMDA antagonist in clinical trials to treat
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"Company receives notice of the issuance of a U.S. patent covering the lead formulation, NRX-101, a glycine site NMDA antagonist in clinical trials to treat bipolar depression with acute and subacute suicidality;This new patent represents a third patent family, that now totals 48 issued patents worldwide with 42 additional pending patent applications.Patent covers the use of NRX-101 to treat patients suffering from depression, including bipolar depression or major depression (MDD) with or without suicidality and strengthens the Company's intellectual property position until at least 2033;Upon approval of NRX-101, this newly granted patent is expected to be \"listable\" in the U.S. Food and Drug Administration (FDA) Orange Book.RADNOR, Pa., Feb. 22, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\", the \"Company\"), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office (\"USPTO\") has issued U.S. Patent No. 11,576,911.\n\n \n \n \n \n \n \n\n \nNRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions-Adds New U.S. PatentThis patent, issued to Glytech LLC, is exclusively licensed to NeuroRx, Inc. (\"NeuroRx\"), a wholly owned subsidiary of NRx, under the terms of a license agreement with Glytech through which NeuroRx has the sole rights to this and other patents, both U.S. and international. The licensed patents cover certain pharmaceutical formulations and their uses in treating a variety of neuropsychiatric conditions, including bipolar depression, major depressive disorder, PTSD, and suicidality. \nIn particular, the claims of the new patent cover methods for treating a patient suffering from depression, including bipolar depression or major depression, with or without suicidality by administering to the patient an effective amount of the Company's lead product candidate, NRX-101. Should this drug candidate be approved by the U.S. Food & Drug Administration (\"FDA\"), this newly issued patent is expected to be listable in the FDA's \"Orange Book\" for NRX-101, which is currently undergoing clinical trials in the U.S. The 'patent represents the U.S. version of a third patent family owned by or exclusively licensed to NeuroRx that covers the NRX-101 formulation or its methods of use in treating depressive...